In the first line, the European Society for Medical Oncology (ESMO) clinical practices guidelines for advanced breast cancer recommend the combination of trastuzumab–pertuzumab–taxane as standard for HER2-positive mBC [7]. Here, ERBB2 is linked to breast cancer.